These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8465094)

  • 1. Tumor necrosis factor/cachectin in Crohn's disease. Relation of serum concentration to disease activity.
    Sategna-Guidetti C; Pulitanò R; Fenoglio L; Bologna E; Manes M; Camussi G
    Recenti Prog Med; 1993 Feb; 84(2):93-9. PubMed ID: 8465094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease.
    Nielsen OH; Brynskov J; Bendtzen K
    Dan Med Bull; 1993 Apr; 40(2):247-9. PubMed ID: 8495600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered subjective appetite parameters in Crohn's disease patients.
    Bannerman E; Davidson I; Conway C; Culley D; Aldhous MC; Ghosh S
    Clin Nutr; 2001 Oct; 20(5):399-405. PubMed ID: 11534934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of diminished factor XIII in Crohn's disease.
    Chamouard P; Grunebaum L; Wiesel ML; Sibilia J; Coumaros G; Wittersheim C; Baumann R; Cazenave JP
    Am J Gastroenterol; 1998 Apr; 93(4):610-4. PubMed ID: 9576457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
    Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
    Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mean platelet volume: a useful marker of inflammatory bowel disease activity.
    Kapsoritakis AN; Koukourakis MI; Sfiridaki A; Potamianos SP; Kosmadaki MG; Koutroubakis IE; Kouroumalis EA
    Am J Gastroenterol; 2001 Mar; 96(3):776-81. PubMed ID: 11280550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
    Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterisation of decoy receptor 3 in Crohn's disease.
    Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
    Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion.
    Clancy R; Ren Z; Turton J; Pang G; Wettstein A
    Dig Liver Dis; 2007 May; 39(5):445-51. PubMed ID: 17317344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
    Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
    Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polymorphism of the microsatellites and tumor necrosis factor genes in chronic inflammatory bowel diseases].
    Heresbach D; Ababou A; Bourienne A; Alizadeh M; Quelvennec E; Pagenault M; Dabadie A; Berre NH; Campion JP; Launois B; Gosselin M; Genetet B; Bretagne JF; Semana G
    Gastroenterol Clin Biol; 1997; 21(8-9):555-61. PubMed ID: 9587492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.
    Dotan I; Fishman S; Dgani Y; Schwartz M; Karban A; Lerner A; Weishauss O; Spector L; Shtevi A; Altstock RT; Dotan N; Halpern Z
    Gastroenterology; 2006 Aug; 131(2):366-78. PubMed ID: 16890590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
    Griga T; May B; Pfisterer O; Müller KM; Brasch F
    Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.